Clinical Investigation High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study - Archive ouverte HAL Access content directly
Journal Articles International Journal of Radiation Oncology, Biology, Physics Year : 2016

Clinical Investigation High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study

(1) , (2) , (3, 4) , (1) , (5) , (6) , (5) , (5) , (1) , (6) , (1) , (1, 3)
1
2
3
4
5
6

Abstract

This study aimed to evaluate the tolerability of zoledro-nate in association with hypofractionated stereotactic radiation therapy (HSRT) for vertebral metastases. The combination of zoledronate and HSRT in the treatment of vertebral metastasis is well tolerated and seems to reduce the rate of vertebral collapse, effectively relieve pain, and achieve good local tumor control with no late neurologic adverse effects. Introduction: Hypofractionated stereotactic radiation therapy (HSRT) for vertebral metastases gives good results in terms of local control but increases the risk of fracture in the treated volume. Preclinical and clinical studies have shown that zoledro-nate not only reduces the risk of fracture and stimulates osteoclastic remodeling but also increases the immune response and radiosensitivity. This study aimed to evaluate the tolerability and effectiveness of zoledronate in association with radiation therapy. Patients and Methods: We conducted a multicenter phase 1 study that combined HSRT (3 Â 9 Gy) and zoledronate in patients with vertebral metastasis (NCT01219790). The principal objective was the absence of spinal cord adverse reactions at 1 year. The secondary objectives were acute tolerability, the presentation of a bone event, local tumor control, pain control, progression-free survival, and overall survival. Results: Thirty patients (25 male, 5 female), median age 66 years, who were followed up for a median period of 19.2 months, received treatment for 49 vertebral me-tastases. A grade 3 acute mucosal adverse event occurred in 1 patient during the treatment and in 2 more at 1 month. No late neurologic adverse events were reported at 1 year. The mean pain scores diminished significantly at 1 month (1.35; PZ.0125)
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01375551 , version 1 (03-10-2016)

Identifiers

Cite

Baptiste Pichon, Loïc Campion, Grégory Delpon, François Thillays, Christian Carrie, et al.. Clinical Investigation High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study. International Journal of Radiation Oncology, Biology, Physics, 2016, [Epub ahead of print]. ⟨10.1016/j.ijrobp.2016.07.027⟩. ⟨inserm-01375551⟩
88 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More